← Cheng Du Sheng Nuo Biotec Co. Ltd. A overview

Cheng Du Sheng Nuo Biotec Co. Ltd. A vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117.CG)

Q3 202612 Jul – 9 Oct 2026

▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.
The half-year report is the core new fundamental event that confirms rapid earnings growth.
Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.
It explains why the earnings growth is credible and not just accounting noise.
Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.
This is the main new risk that can push the share price down and offset the strong earnings.
Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.
It shows the market was already told growth would be strong, which frames the later report.

August 202612 Jul – 9 Oct 2026

▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.
The half-year report is the core new fundamental event that confirms rapid earnings growth.
Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.
It explains why the earnings growth is credible and not just accounting noise.
Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.
This is the main new risk that can push the share price down and offset the strong earnings.
Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.
It shows the market was already told growth would be strong, which frames the later report.

Latest12 Jul – 9 Oct 2026

▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.
The half-year report is the core new fundamental event that confirms rapid earnings growth.
Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.
It explains why the earnings growth is credible and not just accounting noise.
Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.
This is the main new risk that can push the share price down and offset the strong earnings.
Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.
It shows the market was already told growth would be strong, which frames the later report.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.